PGR and breast cancer: BC can be classified into luminal, human epidermal growth factor receptor-2 (HER2), or triple-negative subtypes after immunohistochemical (IHC) analysis of the estrogen receptor (ER), progesterone receptor (PgR), HER2, and Ki-67.